AI Verdict
Both stocks have similar AI ratings. Review detailed metrics below.
SKYE vs PRPH Fundamental Comparison
| Metric | SKYE | PRPH |
|---|---|---|
| Revenue | N/A | $3.6M |
| Net Income | $-55.9M | $-7.3M |
| Net Margin | N/A | -206.3% |
| ROE | -279.3% | -107.1% |
| ROA | -197.5% | -11.2% |
| Current Ratio | 3.30x | 0.14x |
| Debt/Equity | 0.00x | 0.43x |
| EPS | $-1.41 | $-0.19 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
SKYE vs PRPH: Frequently Asked Questions
Is SKYE or PRPH a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), both stocks have similar ratings. SKYE is rated STRONG SELL (97% confidence) while PRPH is rated STRONG SELL (97% confidence). This is not investment advice.
How does SKYE compare to PRPH fundamentally?
Skye Bioscience, Inc. has ROE of -279.3% vs ProPhase Labs, Inc.'s -107.1%. Net margins are N/A vs -206.3% respectively.
Which stock pays higher dividends, SKYE or PRPH?
SKYE has a dividend yield of N/A or no dividend while PRPH has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in SKYE or PRPH for long term?
For long-term investing, consider that SKYE has STRONG SELL rating with 97% confidence, while PRPH has STRONG SELL rating with 97% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about SKYE vs PRPH?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For SKYE vs PRPH, both AIs rate them similarly based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.